Yiling Pharmaceutical Unit Gets Nod to Market Simvastatin Tablets in US

MT Newswires Live
2024/12/02

Shijiazhuang Yiling Pharmaceutical's (SHE:002603) unit, Yiling Wanzhou International Pharmaceutical, received approval from the US Food and Drug Administration to market simvastatin tablets in the US, according to a Shenzhen Stock Exchange filing on Saturday.

The drug is used for patients with coronary heart disease and helps reduce cholesterol and triglyceride levels in patients with hypertriglyceridemia, among other similar uses.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10